Asset Details
Do you wish to reserve the book?
Deep learning-driven morphology analysis enables label-free classification of therapeutic agent- naive versus resistant cancer cells
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Deep learning-driven morphology analysis enables label-free classification of therapeutic agent- naive versus resistant cancer cells
Do you wish to request the book?
Deep learning-driven morphology analysis enables label-free classification of therapeutic agent- naive versus resistant cancer cells
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Paper
Deep learning-driven morphology analysis enables label-free classification of therapeutic agent- naive versus resistant cancer cells
2025
Overview
Therapeutic drug treatments of solid tumors are often undermined by various resistance mechanisms. Identification of drug-resistance phenotypes at the single cell level is challenging because conventional molecular methods are cell-destructive, labor-intensive, and cost-prohibitive. To overcome these challenges, we developed an orthogonal approach to drug-resistance phenotyping, through the use of deep-learning-driven morphology analysis of single, high resolution cell images. Specifically, we trained deep learning-based drug resistance classifiers using cell images from 5 different cell lines that were rendered resistant to 5 different therapeutic agents, using a foundation model framework. With high accuracy, the classifier correctly predicted naive or resistance phenotypes across all cancer types and across all the therapeutic agent types (chemotherapeutic, targeted) tested. These results showed that morphology can capture complex phenotype information in the context of drug treatment. To demonstrate the potential clinical utility of the drug resistance classifier, it was applied to a dissociated tumor biopsy and the resulting phenotype predictions were in close concordance with scRNASeq analysis of the biopsy. Our study highlights the potential of deep-learning-driven morphology analysis to provide complex phenotype information, and ultimately shape oncology drug treatment strategies at the patient-level in a clinical context.Competing Interest StatementEL, MGM, and AD have no conflicts of interest. AJ, KS, ZL, CC, TP, RC, SCB, MR are current or former employees at Deepcell, Inc. SS, VP, MB, CR are current or former employees of Abbvie. MPL has unrelated research funding from Roche, Novartis, Molecular Partners, Oncobit, and Scailyte.
Publisher
Cold Spring Harbor Laboratory Press
Subject
